Novonesis and Novo Nordisk Collaborate to Improve Metabolic Health

Dow Jones09-08

By Dominic Chopping

Danish biotech company Novonesis said it entered a research partnership with Novo Nordisk that will explore new solutions to improve metabolic health and potentially help prevent conditions such as obesity, diabetes and high blood pressure.

The partnership will investigate how the microorganisms that naturally live in the gut, such as bacteria, fungi, and viruses, maintain metabolic health and how they could be used to monitor and predict health in individuals. It will also aim to explore solutions that preserve and optimize metabolic health.

"We are becoming increasingly aware of the role the gut plays in maintaining metabolic health and thereby minimizing the risk of developing obesity," Nadeem Sarwar, head of Novo Nordisk's transformational prevention unit said Monday.

The company's will develop food supplements that combine the live bacteria that are beneficial to the gut, known as probiotics, with the fuel that help these bacteria grow, known as prebiotics. These supplements will be tested for their ability to affect things like blood glucose and cholesterol levels.

"This new collaboration with Novo Nordisk enables us to deepen our understanding of the gut microbiome's role in maintaining metabolic health and to identify innovative products that support it," Henrik Joerck Nielsen, head of human health biosolutions & strategy at Novonesis, said.

Write to Dominic Chopping at dominic.chopping@wsj.com

(END) Dow Jones Newswires

September 08, 2025 07:49 ET (11:49 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2565686613?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-08 19:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2565686613","market":"hk","top_or_hot":-1,"title":"Novonesis and Novo Nordisk Collaborate to Improve Metabolic Health","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Dominic Chopping \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Danish biotech company Novonesis said it entered a research partnership with <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> that will explore new solutions to improve metabolic health and potentially help prevent conditions such as obesity, diabetes and high blood pressure. \n</p>\n<p>\n  The partnership will investigate how the microorganisms that naturally live in the gut, such as bacteria, fungi, and viruses, maintain metabolic health and how they could be used to monitor and predict health in individuals. It will also aim to explore solutions that preserve and optimize metabolic health. \n</p>\n<p>\n  \"We are becoming increasingly aware of the role the gut plays in maintaining metabolic health and thereby minimizing the risk of developing obesity,\" Nadeem Sarwar, head of Novo Nordisk's transformational prevention unit said Monday. \n</p>\n<p>\n  The company's will develop food supplements that combine the live bacteria that are beneficial to the gut, known as probiotics, with the fuel that help these bacteria grow, known as prebiotics. These supplements will be tested for their ability to affect things like blood glucose and cholesterol levels. \n</p>\n<p>\n  \"This new collaboration with Novo Nordisk enables us to deepen our understanding of the gut microbiome's role in maintaining metabolic health and to identify innovative products that support it,\" Henrik Joerck Nielsen, head of human health biosolutions &amp; strategy at Novonesis, said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Dominic Chopping at dominic.chopping@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 08, 2025 07:49 ET (11:49 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novonesis and Novo Nordisk Collaborate to Improve Metabolic Health</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovonesis and Novo Nordisk Collaborate to Improve Metabolic Health\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-09-08 19:49</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Dominic Chopping \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Danish biotech company Novonesis said it entered a research partnership with <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> that will explore new solutions to improve metabolic health and potentially help prevent conditions such as obesity, diabetes and high blood pressure. \n</p>\n<p>\n  The partnership will investigate how the microorganisms that naturally live in the gut, such as bacteria, fungi, and viruses, maintain metabolic health and how they could be used to monitor and predict health in individuals. It will also aim to explore solutions that preserve and optimize metabolic health. \n</p>\n<p>\n  \"We are becoming increasingly aware of the role the gut plays in maintaining metabolic health and thereby minimizing the risk of developing obesity,\" Nadeem Sarwar, head of Novo Nordisk's transformational prevention unit said Monday. \n</p>\n<p>\n  The company's will develop food supplements that combine the live bacteria that are beneficial to the gut, known as probiotics, with the fuel that help these bacteria grow, known as prebiotics. These supplements will be tested for their ability to affect things like blood glucose and cholesterol levels. \n</p>\n<p>\n  \"This new collaboration with Novo Nordisk enables us to deepen our understanding of the gut microbiome's role in maintaining metabolic health and to identify innovative products that support it,\" Henrik Joerck Nielsen, head of human health biosolutions &amp; strategy at Novonesis, said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Dominic Chopping at dominic.chopping@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 08, 2025 07:49 ET (11:49 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2565686613","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2565686613","pubTimestamp":1757332140,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Danish biotech company Novonesis said it entered a research partnership with Novo Nordisk that will explore new solutions to improve metabolic health and potentially help prevent conditions such as obesity, diabetes and high blood pressure.The partnership will investigate how the microorganisms that naturally live in the gut, such as bacteria, fungi, and viruses, maintain metabolic health and how they could be used to monitor and predict health in individuals. It will also aim to explore solutions that preserve and optimize metabolic health.\"We are becoming increasingly aware of the role the gut plays in maintaining metabolic health and thereby minimizing the risk of developing obesity,\" Nadeem Sarwar, head of Novo Nordisk's transformational prevention unit said Monday.\"This new collaboration with Novo Nordisk enables us to deepen our understanding of the gut microbiome's role in maintaining metabolic health and to identify innovative products that support it,\" Henrik Joerck Nielsen, h","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德","NVZMY":"NOVONESIS A S","BK4109":"特种化学制品"},"translate_title":"Novonesis和诺和诺德合作改善代谢健康","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1,"NVZMY":0.9},"content_text":"By Dominic Chopping \n\n\n \n\n\n  Danish biotech company Novonesis said it entered a research partnership with Novo Nordisk that will explore new solutions to improve metabolic health and potentially help prevent conditions such as obesity, diabetes and high blood pressure. \n\n\n  The partnership will investigate how the microorganisms that naturally live in the gut, such as bacteria, fungi, and viruses, maintain metabolic health and how they could be used to monitor and predict health in individuals. It will also aim to explore solutions that preserve and optimize metabolic health. \n\n\n  \"We are becoming increasingly aware of the role the gut plays in maintaining metabolic health and thereby minimizing the risk of developing obesity,\" Nadeem Sarwar, head of Novo Nordisk's transformational prevention unit said Monday. \n\n\n  The company's will develop food supplements that combine the live bacteria that are beneficial to the gut, known as probiotics, with the fuel that help these bacteria grow, known as prebiotics. These supplements will be tested for their ability to affect things like blood glucose and cholesterol levels. \n\n\n  \"This new collaboration with Novo Nordisk enables us to deepen our understanding of the gut microbiome's role in maintaining metabolic health and to identify innovative products that support it,\" Henrik Joerck Nielsen, head of human health biosolutions & strategy at Novonesis, said. \n\n\n \n\n\n  Write to Dominic Chopping at dominic.chopping@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 08, 2025 07:49 ET (11:49 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2565686613","isCrawlerRequest":true}